News

Nutriband Lead Product Aversa(TM) Fentanyl May Reach Peak Annual Sales of $80-200 Million Based on Market Assessment by Leading Healthcare Consulting Firm

Read More »

January 5, 2022

News

Nutriband Inc. Issued Full Patent from the Korean Intellectual Property Office for Its “Abuse and Misuse Deterrent Transdermal System” Application

Read More »

December 31, 2021

News

Nutriband Inc. Announces $1 Million Share Repurchase Authorization

Read More »

December 29, 2021

News

Nutriband Inc. initiates plans to offer Topical lotion contract manufacturing services

Read More »

December 21, 2021

News

Nutriband Inc. Receives cGMP Certification for Manufacturing Subsidiary

Read More »

December 13, 2021

News

Nutriband Inc. to Ring NASDAQ Stock Market Opening Bell on December 3, 2021

Read More »

December 3, 2021

News

Nutriband Inc. Initiates Commercial Development of Lead Product AVERSA(TM) Fentanyl

Read More »

November 16, 2021

News

Nutriband Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Read More »

November 10, 2021

News

Nutriband Inc. Signs Exclusive Manufacturing Agreement for Diocheck(TM) Visual COVID-19 Antibody Indicator Patch

Read More »

October 12, 2021